Axon Strives to Make Bullet Obsolete
Axon Enterprise (NASDAQ:AXON) CEO Rick Smith told the media on Wednesday how the company, which makes technology and equipment for law enforcement, is trying to help police reduce gun use.“We are on a mission to make the bullet obsolete, and specifically cut gun deaths in policing by 50% over the next ten years,” he said. “We’re going to do that with tasers, body cameras, cloud software, and now we’ve got an AI business that’s on fire.”Axon impressed investors when it reported earnings Tuesday night, with shares closing up more than 15% during Wednesday’s session and continuing to see gains in extended trading. The company beat estimates and its forecast was higher than expected, citing high demand for its taser products, as well as its cloud services arm, which accounted for 40% of total revenue.They opened Thursday down $41.27, or 7.2%, to $531.13, Smith described how Axon is using body camera footage and AI to help police write the first transcript of police reports, saying the technology helps departments increase their man power. The AI services the company launched this year are selling five times faster than any product in its history, Smith claimed. He also said that while the company’s “current big thing” is AI, he teased drones as the company’s next major product.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


